Recommendations on integration of radiation therapy with targeted treatments for breast cancer consensus meeting

Florence (IT), 16-17th June 2023

Grand Hotel Mediterraneo, Lungarno del Tempio, 44

Endorsed by
Over the past years, the treatment landscape of breast cancer has significantly evolved. Several new anticancer agents entered clinical use or are in late clinical development. Among them many targeted therapies, including new antibody drug conjugates and immunotherapy agents, have already shown to bring improvements in clinical outcomes, and will therefore likely impact in an increasing manner on the management of breast cancer. The advent of innovative preclinical models has accelerated tumour targets’ identification and subsequent anti-cancer agents’ development, reducing the lag-time between preclinical discoveries and introduction into the clinics. This availability of new therapeutic measures raises the important question on how to integrate them with local and regional treatments, and particularly with radiation therapy, in both curative and advanced settings. The impact of new targeted agents on tumour biology, micro- and immune-environment, and cellular energetics, can alter the clinical outcomes after irradiation.

The purpose of this consensus is to provide preclinical and clinical evidence - and (where lacking) consensus-based guidelines on how to integrate targeted and other agents properly and safely with irradiation to improve the clinical care of patients affected by breast cancer who are candidates for these treatments. An international panel of experts in preclinical and translational research, drug development, and radiation therapy reviewed the available evidence and summarised recommendations to help physicians in daily clinical practice.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Event</th>
<th>Chairs</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 – 09.15</td>
<td>Welcome and introduction Day 1</td>
<td>Lorenzo Livi – Icro Meattini</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.15 – 10.00</td>
<td>Session 1 CDK4/6 inhibitors</td>
<td>Philip Poortmans</td>
<td>Barbara Pistilli</td>
<td>Current clinical evidence</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lucia Del Mastro</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00 – 10.45</td>
<td>Session 2 Anti HER2 therapy (non-ADCs)</td>
<td>Liesbeth Boersma</td>
<td>Cristina Saura</td>
<td>Current clinical evidence</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alessandra Gennari</td>
<td>Sara Alkner</td>
<td></td>
</tr>
<tr>
<td>10.45 – 11.15</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.15 – 11.45</td>
<td>Lecture 1 Innovations in Medical Oncology</td>
<td>Saverio Cinieri – Luca Visani</td>
<td>Giuseppe Curigliano</td>
<td>Phase I clinical trials using molecular targeted agents for breast cancer</td>
</tr>
<tr>
<td>11.45 – 12.15</td>
<td>Lecture 2 Innovations in Radiation Oncology</td>
<td>Frank Vicini – Viola Salvestrini</td>
<td>Asal Shoushtari Rahimi</td>
<td>Integration between modern drugs and preoperative radiation therapy for breast cancer</td>
</tr>
<tr>
<td>12.15 – 13.00</td>
<td>Session 3 ADCs</td>
<td>Lorenzo Livi – Maria Ekholm</td>
<td>Hope Rugo</td>
<td>Current clinical evidence</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tanja Skytta</td>
<td></td>
</tr>
<tr>
<td>13.00 – 14.30</td>
<td>Lunch</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
14.30 – 15.00  **Lecture 3**  
Chairs  
Gustavo Nader Marta  
Andrea Morandi  
Speaker  
Elisabetta Marangoni  
**Title**  
*How to best model breast cancer to study drug-radiation therapy interaction*

15.00 – 15.30  **Session 4**  
Chairs  
Matteo Lambertini  
Birgitte V. Offersen  
Speaker  
Orit Kaidar-Person  
**Title**  
*Optimal requirements for assessing radiation therapy interaction with drugs in clinical trials*

15.30 – 16.00  **Lecture 4**  
Chairs  
Sven Rottenberg  
Icro Meattini  
Speaker  
Philip Poortmans  
**Title**  
*Interaction between metastatic risk/efficacy of systemic treatments and the effects of locoregional treatments on survival*

16.00 – 16.30  **Lecture 5**  
Chairs  
Maurizio Callari  
Carlotta Becherini  
Speaker  
Tanja Spanic  
**Title**  
*Patient advocate involvement in the design and conduct of breast cancer clinical trials*

16.30 – 16.45  **Remarks Day 1**  
Chairs  
Lorenzo Livi  
Philip Poortmans
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair(s)</th>
<th>Speaker(s)</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 – 09.15</td>
<td>Welcome and introduction Day 2</td>
<td>Icro Meattini, Matteo Lambertini</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.15 – 09.45</td>
<td>Lecture 6</td>
<td>Marcos Malumbres, Robert Clarke</td>
<td>Clare Isacke</td>
<td>Highlights of the preclinical studies on radiation therapy-drug interaction in breast cancer</td>
</tr>
<tr>
<td>09.45 – 10.30</td>
<td>Session 5</td>
<td>Charlotte E. Coles, Gil Morgan</td>
<td>Javier Cortes</td>
<td>Current clinical evidence</td>
</tr>
<tr>
<td>10.30 – 11.00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00 – 11.45</td>
<td>Session 6</td>
<td>Ingvil Mjaaland, Javier Cortes</td>
<td>Shani Paluch-Shimon</td>
<td>Current clinical evidence Integration with radiation therapy</td>
</tr>
<tr>
<td>11.45 – 12.30</td>
<td>ESTRO consensus recommendations</td>
<td>Icro Meattini, Matteo Lambertini, Andrea Morandi, Saverio Caini &amp; Faculty</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30 – 13.00</td>
<td>Take Home Messages and Closing Remarks</td>
<td>Lorenzo Livi, Philip Poortmans</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Faculty

Carlotta Becherini, Florence, Italy
Saverio Caini, Florence, Italy
Charlotte Coles, Cambridge, UK
Javier Cortes, Barcelona, Spain
Clare Isacke, London, UK
Orit Kaidar-Person, Sheba Tel Hashomer, Israel
Matteo Lambertini, Genoa, Italy
Lorenzo Livi, Florence, Italy
Elisabetta Marangoni, Paris, France
Icro Meattini, Florence, Italy
Andrea Morandi, Florence, Italy
Birgitte Offersen, Aarhus, Denmark
Philip Poortmans, Antwerp, Belgium
Hope Rugo, San Francisco, USA
Viola Salvestrini, Florence, Italy
Luca Visani, Florence, Italy
Speakers and Chairs

Sara Alkner
Lund, Sweden
Liesbeth Boersma
Maastricht, The Netherlands
Maurizio Callari
Milan, Italy
Saverio Cinieri
Brindisi, Italy
Robert Clarke
Manchester, UK
Giuseppe Curigliano
Milan, Italy
Lucia Del Mastro
Genoa, Italy
Maria Ekholm
Jönköping, Sweden
Alessandra Gennari
Novara, Italy
Stephanie Kroeze
Zurich, Switzerland
Marcos Malumbres
Madrid, Spain
Ingvil Mjaaland
Stavanger, Norway

Gustavo Nader Marta
São Paulo, Brazil
Gil Morgan
Lund, Sweden
Shani Paluch-Shimon
Jerusalem, Israel
Barbara Pistilli
Paris, France
Sofia Rivera
Paris, France
Sven Rottenberg
Bern, Switzerland
Asal Shoushtari Rahimi
Dallas, USA
Cristina Saura
Barcelona, Spain
Tanja Skyttä
Tampere, Finland
Tanja Spanic
Ljubljana, Slovenia
Frank Vicini
Royal Oak, USA
Secretariat Organization

APRICOT VIAGGI

Via Statale Lucchese,183
51034 Serravalle Pistoiese (PT)
Phone: +39 0573.518288

Sponsor team
Brunella Bracali
E-mail: brunella@apricotviaggi.it
Mob: +39 331.2061941

Accommodation team
Alice Ricci
E-mail: alice@apricotviaggi.it
Mob: +39 335.7556043

Provider
MDG Solutions
ECM Accredited Event ID
7259-375007

Recipients of the initiative
Doctors and Surgeons

Disciplines
Oncology, radiotherapy, general surgery, radiodiagnostics, radiology, pathological anatomy, biochemistry, pharmacology and clinical toxicology.

Registration and Information Payment
The full registration fee is €100.00

Registration fee has be to be paid in euro.
1. By credit card Visa, Mastercard, American Express
(To receive information please contact this address email: alice@apricotviaggi.it)
2. By Bank transfer IBAN IT78A020081380700005120560
Bank Name Unicredit
Swift Code BIC UNCRITM1G28
Please add your full name and “ESTRO Florence” in the bank transfer description while paying.
Congress Venue

Grand Hotel Mediterraneo
Lungarno del Tempio, 44 - Florence
Phone: +39 055.660241